Citius Pharma Overview
- Year Founded
-
2007
- Status
-
Public
- Employees
-
23
- Stock Symbol
-
CTXR
- Investments
-
3
- Share Price
-
$0.50
- (As of Friday Closing)
Citius Pharma General Information
Description
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
Contact Information
Website
www.citiuspharma.comCorporate Office
- 11 Commerce Drive
- First Floor
- Cranford, NJ 07016
- United States
Corporate Office
- 11 Commerce Drive
- First Floor
- Cranford, NJ 07016
- United States
Citius Pharma Timeline
Citius Pharma Stock Performance
As of 20-Nov-2026, Citius Pharma’s stock price is $0.50. Its current market cap is $14M with 27.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.50 | $0.50 | $0.37 - $1.54 | $14M | 27.5M | 275K | -$1.75 |
Citius Pharma Financials Summary
As of 30-Jun-2026, Citius Pharma has a trailing 12-month revenue of $7.11M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 30-Sep-2025 | FY 2024 30-Sep-2024 | FY 2023 30-Sep-2023 |
|---|---|---|---|---|
| EV | 20,356 | 19,390 | 73,480 | 76,574 |
| Revenue | 7,105 | 0 | 0 | 0 |
| EBITDA | (57,602) | (38,311) | (39,398) | (32,952) |
| Net Income | (46,274) | (37,434) | (39,139) | (32,543) |
| Total Assets | 142,255 | 130,938 | 116,652 | 103,611 |
| Total Debt | 7,177 | 1,813 | 263 | 481 |
Citius Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Citius Pharma Comparisons
Industry
Financing
Details
Citius Pharma Competitors (50)
One of Citius Pharma’s 50 competitors is Merck & Co., a Corporation company based in Rahway, NJ.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Merck & Co. | Corporation | Rahway, NJ | ||||
| Roivant Sciences | Formerly PE-Backed | New York, NY | ||||
| Kodiak Sciences | Formerly VC-backed | Palo Alto, CA | ||||
| Gilead | Formerly VC-backed | Foster City, CA | ||||
| Cynata Therapeutics | Corporation | Cremorne, Australia |
Citius Pharma Patents
Citius Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240358716-A1 | Halobetasol propionate-lidocaine formulations | Pending | 27-Apr-2023 | ||
| US-20260174783-A1 | Halobetasol propionate-lidocaine formulations | Pending | 27-Apr-2023 | ||
| WO-2024227098-A1 | Halobetasol propionate-lidocaine formulations | Inactive | 27-Apr-2023 | ||
| US-20240358321-A1 | Methods and systems for assessing hemorrhoids and treatment effectiveness thereof | Pending | 27-Apr-2023 | ||
| WO-2024227106-A1 | Methods and systems for assessing hemorrhoids and treatment effectiveness thereof | Inactive | 27-Apr-2023 | G16H50/20 |
Citius Pharma Signals
Citius Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Citius Pharma Investments & Acquisitions (3)
Citius Pharma’s most recent deal was a Corporate Asset Purchase with Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) for . The deal was made on 07-Sep-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Dr. Reddy (License for Late-Phase 3 Oncology Immunotherapy - E7777) | 07-Sep-2021 | Corporate Asset Purchase | Buildings and Property | ||
| Leonard-Meron Biosciences | 04-Apr-2016 | Merger/Acquisition | Drug Discovery | ||
| Trail One | 12-Sep-2014 | Merger/Acquisition | Automotive |
Citius Pharma ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
39.71 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Citius Pharma FAQs
-
When was Citius Pharma founded?
Citius Pharma was founded in 2007.
-
Where is Citius Pharma headquartered?
Citius Pharma is headquartered in Cranford, NJ.
-
What is the size of Citius Pharma?
Citius Pharma has 23 total employees.
-
What industry is Citius Pharma in?
Citius Pharma’s primary industry is Pharmaceuticals.
-
Is Citius Pharma a private or public company?
Citius Pharma is a Public company.
-
What is Citius Pharma’s stock symbol?
The ticker symbol for Citius Pharma is CTXR.
-
What is the current stock price of Citius Pharma?
As of 20-Nov-2026 the stock price of Citius Pharma is $0.50.
-
What is the current market cap of Citius Pharma?
The current market capitalization of Citius Pharma is $14M.
-
What is Citius Pharma’s current revenue?
The trailing twelve month revenue for Citius Pharma is $7.11M.
-
Who are Citius Pharma’s competitors?
Merck & Co., Roivant Sciences, Kodiak Sciences, Gilead, and Cynata Therapeutics are some of the 50 competitors of Citius Pharma.
-
What is Citius Pharma’s annual earnings per share (EPS)?
Citius Pharma’s EPS for 12 months was -$1.75.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process